Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Meningococcal Disease: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Meningococcal Disease: 4 US clinical trials tracked, none currently recruiting.
Meningococcal Disease is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Vaccines, running 2 of these trials.
Enrollment posture brief
Registry condition meningococcal-disease
OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Meningococcal Disease has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Meningococcal Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Meningococcal Disease is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Safety Surveillance of MenACWY-CRM Vaccine in Children
Novartis Vaccines
NCT01452438
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
Novartis Vaccines
NCT01992536
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
GlaxoSmithKline
NCT02287688
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
GlaxoSmithKline
NCT02223637
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Meningococcal Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Meningococcal Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Meningococcal Disease page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Meningococcal Disease trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Novartis Vaccines sponsors the most Meningococcal Disease trials on record, review their full trial history before evaluating a specific study. See Novartis Vaccines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Meningococcal Disease condition card totals 4 registered trials; most-linked intervention Meningococcal quadrivalent CRM-197 conjugate vaccine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.